Thursday, July 5, 2018
08:00 - 08:30 am Conference opening
08:30 - 08:35 am Welcome remarks - Lawrence Serfaty (France)
08:35 - 08:45 am Inauguration Address - Stanislas Pol (France)
08:45 - 10:15 am SESSION 1 • NASH EPIDEMIOLOGY AND PUBLIC HEALTH
Chairs: Patrick Marcellin (France) and Michael Trauner (Austria)
08:45 - 09:05 am The value proposition of NASH therapy on the burden of disease related to obesity.
09:05 - 09:25 am The evolution of NASH from childhood to adulthood.
Joel Lavine (USA)
09:25 - 09:45 am What is needed to put NASH on the radar for WHO- lessons learned from viral hepatitis.
Jean-Michel Pawlotsky (France) and Speaker TBC
09:45 - 10:15 am Discussion
10:15 - 10:45 am COFFEE BREAK AND POSTERS
10:45 - 12:15 pm SESSION 2 • CARDIO-METABOLIC MORBIDITY AND MORTALITY DUE TO NAFLD
Chairs: Scott Friedman (USA) and Fabio Marra (Italy)
10:45 - 11:05 am Does reversal of NASH reverse cardiovascular risk?
Bart Staels (France)
11:05 - 11:25 am Is type 2 diabetes and NASH the same disease affecting different organs?
Bertrand Cariou (France)
11:25 - 11:45 am Acceleration of cardiometabolic disease after liver transplantation for NASH.
Mohammad Siddiqui (USA)
11:45 - 12:15 pm Discussion
12:15 - 12:45 pm SESSION 3 • CLINICAL STATE OF THE ART LECTURE
Chair: Philippe Mathurin (France)
12:15 - 12:45 pm The pathophysiological, clinical and regulatory implications of alcohol consumption in Non Alcoholic SteatoHepatitis.
Arun Sanyal (USA)
12:45 - 02:00 pm LUNCH AND POSTERS
02:00 - 03:50 pm SESSION 4 • PRECISION MEDICINE FOR NASH
Chairs: Quentin Anstee (United Kingdom) and Lawrence Serfaty (France)
02:00 - 02:20 pm Molecular markers of disease progression in NASH.
Jean-François Dufour (Switzerland)
02:20 - 02:40 pm Phenotyping NAFLD based on whole body morphometry.
Olof Dahlqvist Leinhard (Sweden)
02:40 - 03:00 pm Phenotyping NAFLD based on the gut microbiome.
03:00 - 03:20 pm The potential use of iPSC to guide Precision Medicine for NASH.
03:20 - 03:50 pm Discussion
03:50 - 04:15 pm COFFEE BREAK AND POSTERS
04:15 - 5:45 pm SESSION 5 • TECHNOLOGIC INNOVATIONS IN NASH
Chairs: Jean-Pierre Bronowicki (France) and Frank Tacke (Germany)
04:15 - 04:35 pm Radiomics and imaging inflammation in solid organs.
Richard Ehman (USA)
04:35 - 04:55 pm The protease signature of NASH.
04:55 - 05:15 pm Gut-based immunotherapy - implications for NASH.
05:15 - 05:45 pm Discussion
05:45 - 06:00 pm POSTER AWARDS
Friday, July 6, 2018
08:00 - 08:30 am WELCOME DESK OPENING
08:30 - 10:20 am SESSION 6 • NAFLD and HCC
Chairs: Stanislas Pol (France) and Manuel Romero-Gómez (Spain)
08:30 - 08:50 am Clinical and Pathological characteristics of steatohepatitis HCC.
Pierre Bedossa (France)
08:50 - 09:10 am Immune mechanisms in the genesis of HCC due to NASH.
Frank Tacke (Germany)
09:10 - 09:30 am Epigenetic basis for NASH associated HCC.
Igor Pogribny (USA)
09:30 - 09:50 am How will new therapies affect HCC development ?
Scott Friedman (USA)
09:50 - 10:20 am Discussion
10:20 - 10:40 am COFFEE BREAK
10:40 - 12:00 pm SESSION 7 • PATIENT CENTERED APPROACH TO NASH
Chairs: Mohammad Siddiqui (USA) and Zobair Younossi (USA)
10:40 - 11:00 am Development of a patient reported outcomes instrument for NASH that meets regulatory standards.
Maria Magdalena Balp (United Kingdom)
11:00 - 11:20 am The science and art of patient-engaged trial design.
11:20 - 11:40 am The burden of cirrhosis on their caregivers.
Jasmohan Bajaj (USA)
11:40 - 12:00 pm Discussion
12:00 - 12:30 pm SESSION 8 • REGULATORY LANDSCAPE
Chair: Lawrence Serfaty (France)
12:00 - 12:20 pm Regulatory Update.
Veronica Miller (USA)
12:20 - 12:30 pm Discussion
12:30 - 02:00 pm LUNCH BREAKOUT SESSION
GROUP 1: Epidemic of NAFLD in US and EU: is disease-related morbi/mortality overestimated?
Philippe Mathurin (France) and Zobair Younossi (USA)
GROUP 2: Screening of HCC : can we assess the risk in non cirrhotic patients?
Fabio Marra (Italy) and Valérie Paradis (France)
GROUP 3: Epigenetic mechanisms as driver of disease inheritance and disease progression.
Massimo Levrero (France) and Pierre-Emmanuel Rautou (France)
GROUP 4: Weight loss: pharmacological and non-pharmacological interventions.
Guillaume Lassailly (France) and Manuel Romero-Gómez (Spain)
02:00 - 03:00 pm SESSION 9 • TRIAL DESIGN
Chairs: Veronica Miller (USA) and Arun Sanyal (USA)
02:00 - 02:20 pm Master - protocols in NASH - challenges and opportunities.
02:20 - 02:40 pm Learning from placebo responses in current trials to improve future trial design.
Quentin Anstee (United Kingdom)
02:40 - 03:00 pm Discussion
03:00 - 04:30 pm SESSION 10 • ROUND TABLE
Chairs: Arun Sanyal (USA) and Lawrence Serfaty (France)
03:00 - 04:30 pm Building synergy between patient advocacy and drug development for NASH.
Panelists: Quentin Anstee (United Kingdom), Dean Hum (France), Omoro Omoighe (USA), Manuel Romero-Gómez (Spain), 2 speakers TBC, EU patient representative (name TBC)
04:30 pm CONCLUDING REMARKS
Arun Sanyal (USA)